Flputnam Investment Management Co. Purchases 27,425 Shares of Johnson & Johnson $JNJ

Key Points

• Flputnam Investment Management increased its Johnson & Johnson stake by 40.4% in the second quarter, buying 27,425 shares for a total holding of 95,241 shares valued at approximately $24.2 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported quarterly EPS of $2.90, beating estimates of $2.84, while revenue rose 6.6% year over year to $25.31 billion. Analysts maintain a “Moderate Buy” consensus with an average price target of $268.22.
• The company declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and a 2.0% yield. Recent business developments include expanded drug approvals and product growth that may help offset pressure from the STELARA patent loss.

Flputnam Investment Management Co. boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 40.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,241 shares of the company's stock after acquiring an additional 27,425 shares during the period. Flputnam Investment Management Co.'s holdings in Johnson & Johnson were worth $24,188,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Blueline Advisors LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at about $25,000. Cresta Advisors Ltd. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Bay Harbor Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after purchasing an additional 49 shares during the last quarter. Matrix Trust Co lifted its stake in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. boosted its holdings in Johnson & Johnson by 946.7% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after acquiring an additional 142 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. The trade was a 48.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 63,972 shares of company stock valued at $16,245,605. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $268.30 on Friday. The company's fifty day moving average price is $258.88 and its 200-day moving average price is $243.94. The stock has a market cap of $646.58 billion, a PE ratio of 31.09, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $276.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson's revenue was up 6.6% on a year-over-year basis. During the same period last year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's payout ratio is presently 62.11%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J's oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock's surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. TD Cowen boosted their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Royal Bank Of Canada upped their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Argus set a $300.00 target price on Johnson & Johnson in a research note on Wednesday, July 29th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. Finally, Johnson Rice reaffirmed a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $268.22.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source